Prof.Dr. Didem TAŞTEKİN

Kişisel Bilgiler

E-posta: didem.tastekin@istanbul.edu.tr
Web: https://avesis.istanbul.edu.tr/didem.tastekin

Uluslararası Araştırmacı ID'leri
ORCID: 0000-0002-9522-9849
Publons / Web Of Science ResearcherID: AAZ-7289-2020
Yoksis Araştırmacı ID: 257156

Eğitim Bilgileri

Tıpta Uzmanlık, Atatürk Üniversitesi, Tıp Fakültesi, Türkiye 2001 - 2005
Lisans, Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi, Türkiye 1988 - 1994

Araştırma Alanları

Tıp, Sağlık Bilimleri, Dahili Tıp Bilimleri, İç Hastalıkları, Onkoloji, Cerrahi Tıp Bilimleri, Genel Cerrahi, Cerrahi Onkoloji

Akademik Unvanlar / Görevler

Doktor, İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Onkoloji Enstitüsü, 2005 - Devam Ediyor

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

I. **Comparison of efficacy and safety of 5-FU or capecitabine combined with cisplatin and docetaxel (mDCF and mDCX) as a first-line chemotherapy regimen in her 2-negative metastatic gastric cancer patients: A retrospective study**
DEMİRCİ N. S., AZİZY A., Paksoy N., Doğan I., KARABULUT S., Karahan L., TAŞTEKİN D.
Medicine (United States), cilt.103, sa.9, 2024 (SCI-Expanded)

II. **The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing**
KÖSTEK O., Demirel A., Hacıoğlu M. B., TAŞTEKİN D., KARABULUT S., Gündogdu A., Sever N., Ayhan M., Çelebi A., Majidova N., et al.
Journal of Chemotherapy, 2024 (SCI-Expanded)

III. **Investigation of the potential of miRNA candidates as non-invasive biomarkers for the diagnosis and follow-up of colorectal cancer**
Karabulut S., Şen S., Oğuz Soydinç H., Doğan I., Taştekin D., Karabulut M., Duman M., Turan M.
Pathology - Research and Practice, cilt.254, ss.1-7, 2024 (SCI-Expanded)

IV. **Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group**
Ünal Ç., AZİZY A., KARABULUT S., TAŞTEKİN D., AKYILDIZ A., YAŞAR S., YALÇIN Ş., Çoban E., EVRENSEL T., Kalkan Z., et al.
The oncologist, cilt.28, sa.10, ss.875-884, 2023 (SCI-Expanded)

V. **Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience**
TAŞTEKİN D., Paksoy N., DOĞAN İ., Ferhatoglu F., KHANMAMMADOV N., Bozbey H. U., KARABULUT S.
Journal of cancer research and therapeutics, cilt.19, sa.2, ss.253-258, 2023 (SCI-Expanded)

VI. **Neoadjuvant intermediate-course versus long-course chemoradiotherapy in T3-4/N0+rectal cancer: Istanbul R-02 phase II randomized study**
Senyurek S., Saglam S., Saglam E. K., Yanar H., Gok K., TAŞTEKİN D., Akbas C., Sakin N. D., Kartal G. D., Balik E., et al.
ONCOLOGY RESEARCH, cilt.31, sa.5, ss.689-696, 2023 (SCI-Expanded)

VII. **Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group**
Erol C., Nahit Sendur M. A., Bilgetekin I., Garbioglu D. B., Hamdard J., Akbas S., Hizal M., Arslan C., Sevinc A., Kucukarda A., et al.
Journal of cancer research and therapeutics, cilt.18, 2022 (SCI-Expanded)

VIII. **Quantification of cell-free circulating mitochondrial DNA copy number variation in hepatocellular carcinoma**
Yalcinkaya B., Tastekin D., Guezelbulut F., Akgoz M., PENÇE S.
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, cilt.68, sa.9, ss.1161-1165, 2022 (SCI-Expanded)

IX. **Does nutritional status affect treatment tolarability, response and survival in metastatic colorectal cancer patients? Results of a prospective multicenter study**
Karabulut S., Dogan I., Usul Afsar C., Karabulut M., Karaman S., Ferhatoglu F., Tastekin D.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.27, sa.6, ss.1357-1363, 2021 (SCI-Expanded)

X. **Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.**
Dogan I., Tastekin D., Karabulut S., Sakar B.
JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.3, 2021 (SCI-Expanded)

XI. **Role of mir-33a, mir-203b, mir361-3p, and mir-424 in hepatocellular carcinoma**
Yalcinkaya B., Guzel Tanoglu E., Tastekin D., Pence S.
TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.51, sa.2, ss.638-643, 2021 (SCI-Expanded)

XII. **Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey**
Hacioglu M. B., Kostek O., Karabulut S., Tastekin D., SEZGİN GÖKSU S., Alandag C., Akagunduz B., Bilgetekin I., Caner B., ŞAHİN A. B., et al.
JOURNAL OF BUON, cilt.25, sa.4, ss.1897-1903, 2020 (SCI-Expanded)

XIII. **Investigation of JAM-A (rs790056) and LFA-1 (rs8058823) gene variants in Turkish colorectal cancer patients**
Caykara B., Alsaadoni H., Pence H. H., Pence S., Aydogan H., Tastekin D.
TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.30, sa.10, ss.872-876, 2019 (SCI-Expanded)

XIV. **ROLE OF INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) AND INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 (IGFBP-3) IN THE DIAGNOSIS OF PANCREATIC ADENOCARCINOMA AND MONITORING TREATMENT RESPONSE**
Bademler S., Ucuncu W. Z., Sari M., Yasasever C., Afsar C. U., Tastekin D.
ACTA MEDICA MEDITERRANEA, cilt.35, sa.1, ss.71-75, 2019 (SCI-Expanded)

XV. **Evaluation of JAM-A (rs790056) and LFA-1 (rs8058823) Variants in Colorectal Cancer**
Caykara B., Alsaadoni H., PENÇE H. H., Pence S., Aydogan H., Tastekin D.
ACTA PHYSIOLOGICA, cilt.225, ss.25, 2018 (SCI-Expanded)

XVI. **Neoadjuvant volumetric modulated arc therapy in rectal cancer and the correlation of pathological response with diffusion-weighted MRI and apoptotic markers.**
Gurdal N., Fayda M., ALISHEV N., Bakir B., Tastekin D., Aykan F., Gezer U., Balik E., Saglam E., Oral E. N., et al.
Tumori, cilt.104, ss.266-272, 2018 (SCI-Expanded)

XVII. **Prognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases: A retrospective analysis of multicenter study (Anatolian**

Society of Medical Oncology)

Inal A., Kodaz H., Odabas H., Duran A. O., ŞEKER M. M., Inanc M., ELKIRAN E. T., Gunaydin Y., Menekse S., Topcu T. O., et al.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, cilt.14, sa.3, ss.578-582, 2018 (SCI-Expanded)

XVIII. **Evaluation of Prognostic Factors and Adjuvant Chemotherapy in Patients With Small Bowel Adenocarcinoma Who Underwent Curative Resection**

Aydin D., Sendur M. A., KEFELİ U., Unal O. U., Tastekin D., Akyol M., Tanrikulu E., Ciltas A., Ustaalioglu B. B., Uysal M., et al.

CLINICAL COLORECTAL CANCER, cilt.16, sa.3, ss.220-227, 2017 (SCI-Expanded)

XIX. **Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO)**

Aydin D., Sendur M. A., KEFELİ U., Unal O. U., TAŞTEKİN D., Akyol M., Tanrikulu E., Ciltas A., Ustaalioglu B. B., ŞENER DEDE D., et al.

JOURNAL OF BUON, cilt.21, sa.5, ss.1242-1249, 2016 (SCI-Expanded)

XX. **Serum activated leukocyte cell adhesion molecule and intercellular adhesion molecule-1 in patients with gastric cancer: Can they be used as biomarkers?**

Erturk K., Tastekin D., Bilgin E., Serilmez M., Bozbey H. U., Sakar B.

BIOMEDICINE & PHARMACOTHERAPY, cilt.77, ss.86-91, 2016 (SCI-Expanded)

XXI. **Is it solitary plasmacytoma or nonsecretory myeloma? A must-be-solved dilemma?**

Erturk K., Tastekin D., Gundogdu G., Tas F., Vatansever S.

BIOMEDICINE & PHARMACOTHERAPY, cilt.77, ss.27-29, 2016 (SCI-Expanded)

XXII. **Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer**

Erturk K., Tastekin D., Serilmez M., Bilgin E., Bozbey H. U., Vatansever S.

TUMOR BIOLOGY, cilt.37, sa.1, ss.405-412, 2016 (SCI-Expanded)

XXIII. **The relationship of beck depression inventory with vitamin D levels and visceral fat mass in cancer patients**

Tuna S., Mert M., Soyluk O., Okuturlar Y., Kocoglu H., Tastekin D.

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, cilt.9, sa.5, ss.8719-8724, 2016 (SCI-Expanded)

XXIV. **Clinical significance of serum protease activated receptor1 levels in patients with lung cancer**

Erturk K., Tastekin D., Bilgin E., Tas F., Disci R., Duranyildiz D.

European Review for Medical and Pharmacological Sciences, cilt.20, sa.2, ss.243-249, 2016 (SCI-Expanded)

XXV. **Bilateral Cystoid Macular Edema Secondary to Paclitaxel Treatment**

Tezcan Y., Surmeli M., Tastekin D., Koc M.

ARCHIVES OF IRANIAN MEDICINE, cilt.18, sa.9, ss.606-607, 2015 (SCI-Expanded)

XXVI. **Plasma homocysteine, folate and vitamin B12 levels in patients with lung cancer.**

Tastekın D., Erturk K., Bozbey H. U., Olmuscelık O., Kızıltan H., Tuna S., Tas F.

Experimental oncology, cilt.37, ss.218-22, 2015 (SCI-Expanded)

XXVII. **Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma**

Turan N., Benekli M., Unal O. U., Unek I. T., Tastekin D., Dane F., Algin E., Ulger S., Eren T., Topcu T. O., et al.

CHINESE JOURNAL OF CANCER RESEARCH, cilt.27, sa.4, ss.408-416, 2015 (SCI-Expanded)

XXVIII. **Prognostic factors in clinical stage T4N2 locally advanced non-small cell lung cancer**

Arslan D., Tural D., Koca T., Tastekin D., Cerkesli A. K., Basaran H., Gunduz S., Tatli A. M., Goksu S. S., UYSAL M., et al.

JOURNAL OF BUON, cilt.20, sa.2, ss.573-579, 2015 (SCI-Expanded)

XXIX. **Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer.**

Tas F., Yasasever C. T., Karabulut S., Tastekin D., Duranyildiz D.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, cilt.36, sa.3, ss.2097-103, 2015 (SCI-Expanded)

XXX. **Radioprotectant and Cytotoxic Effects of Spirulina in Relapsed Verrucous Vulvar Cancer: A Case Report**
KIZILTAN H. Ş., GÜNEŞ BAYIR A., Taspinar O., Yucesan G., Tastekin D., Sonmez F. C., ÇOBAN G., KILIC G., Eris A. H., AYDIN T., et al.
ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE, cilt.21, ss.68-72, 2015 (SCI-Expanded)

XXXI. **Alpha-fetoprotein (AFP) elevation gastric adenocarcinoma and importance of AFP change in tumor response evaluation**
Tatli A. M., Urakci Z., Kalender M. E., Arslan H., TAŞTEKİN D., Kaplan M. A.
Asian Pacific Journal of Cancer Prevention, cilt.16, sa.5, ss.2003-2007, 2015 (SCI-Expanded)

XXXII. **Circulating annexin A2 as a biomarker in gastric cancer patients: Correlation with clinical variables**
Tas F., Yasasever C. T., Karabulut S., Tastekin D., Duranyildiz D.
Biomedicine and Pharmacotherapy, cilt.69, ss.237-241, 2015 (SCI-Expanded)

XXXIII. **Progesterone receptor status in determining the prognosis of estrogen receptor positive/HER2 negative breast carcinoma patients**
Bal O., Arslan U. Y., Durnali A., Uyetrk U., Demirci A., Tastekin D., Ekinci A., Esbah O., Turker I., Sonmez O. U., et al.
JOURNAL OF BUON, cilt.20, sa.1, ss.28-34, 2015 (SCI-Expanded)

XXXIV. **The efficacy of Pistacia Terebinthus soap in the treatment of cetuximab-induced skin toxicity**
Tastekin D., Tambas M., KILIC K., Erturk K., ARSLAN D.
INVESTIGATIONAL NEW DRUGS, cilt.32, sa.6, ss.1295-1300, 2014 (SCI-Expanded)

XXXV. **Synuclein-gamma predicts poor clinical outcome in esophageal cancer patients**
Tastekin D., Kargin S., KARABULUT M., Yaldiz N., Tambas M., Gurdal N., TATLI A. M., Arslan D., Gok A. F. K., Aykan F.
TUMOR BIOLOGY, cilt.35, sa.12, ss.11871-11877, 2014 (SCI-Expanded)

XXXVI. **Clinical significance of serum fibronectin and vitronectin levels in melanoma patients**
Tas F., Karabulut S., Bilgin E., Tastekin D., Duranyildiz D.
MELANOMA RESEARCH, cilt.24, sa.5, ss.475-479, 2014 (SCI-Expanded)

XXXVII. **The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EpCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer**
Karabulut S., Tas F., Tastekin D., KARABULUT M., Yasasever C., Ciftci R., Guveli M., Fayda M., Vatansever S., Serilmez M., et al.
TUMOR BIOLOGY, cilt.35, sa.9, ss.8849-8860, 2014 (SCI-Expanded)

XXXVIII. **Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer.**
TURAN N., Benekli M., DANE F., Unal O. U., Kara H. V., KOCA D., BALVAN O., EREN T., Tastekin D., HELVACI K., et al.
Thoracic cancer, cilt.5, sa.5, ss.398-404, 2014 (SCI-Expanded)

XXXIX. **Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in patients with breast cancer**
Tas F., Karabulut S., Bilgin E., Tastekin D., Duranyildiz D.
TUMOR BIOLOGY, cilt.35, sa.9, ss.9303-9309, 2014 (SCI-Expanded)

XL. **Clinical significance of serum tenascin-c levels in epithelial ovarian cancer**
Didem T., Faruk T., Senem K., Derya D., Murat S., Murat G., OZNUR K.
TUMOR BIOLOGY, cilt.35, sa.7, ss.6777-6782, 2014 (SCI-Expanded)

XLI. **Clinical significance of serum tenascin-C levels in breast cancer**
Tastekin D., Tas F., Karabulut S., Duranyildiz D., Serilmez M., Guveli M., Vatansever S.
TUMOR BIOLOGY, cilt.35, sa.7, ss.6619-6625, 2014 (SCI-Expanded)

XLII. **Assessment of tumor characteristics and factors affecting survival in patients with primary metastatic breast carcinoma: a Multicenter Study of the Anatolian Society of Medical Oncology**
Uyeturk U., Oksuzoglu B., Akman T., Turker I., Sener N., Tastekin D., Bal O., Berk V., Arslan U. Y., Urakci Z., et al.
MEDICAL ONCOLOGY, cilt.31, sa.4, 2014 (SCI-Expanded)

XLIII. **Outcome of Daily Cisplatin with Thoracic Chemoradiotherapy in Advanced Non-small Cell Lung Cancer Patients with Comorbid Disorders: a Pilot Study**
KIZILTAN H. Ş., Bayir A. G., Tastekin D., ÇOBAN G., Eris A. H., AYDIN T., Mayadagli A.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, cilt.15, sa.20, ss.8591-8594, 2014 (SCI-Expanded)

XLIV. **Clinicopathologic Features and Molecular Subtypes of Breast Cancer in Young Women (Age <= 35)**
Goksu S. S., Tastekin D., Arslan D., Gunduz S., TATLI A. M., Unal D., Salim D., Guler T., COŞKUN H. Ş.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, cilt.15, sa.16, ss.6665-6668, 2014 (SCI-Expanded)

XLV. **Impact of Poster Presentations on Academic Knowledge Transfer from the Oncologist Perspective in Turkey**
Arslan D., Koca T., Tastekin D., Basaran H., Bozcuk H.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, cilt.15, sa.18, ss.7707-7711, 2014 (SCI-Expanded)

XLVI. **Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma**
Tas F., Karabulut S., Bilgin E., Sen F., Yildiz I., Tastekin D., Ciftci R., Duranyildiz D.
TUMOR BIOLOGY, cilt.34, sa.6, ss.3529-3536, 2013 (SCI-Expanded)

XLVII. **Rectal cancer in pregnancy: a case report and review of the literature.**
Dogan N., Tastekin D., Kerimoglu O., Pekin A., Celik C.
Journal of gastrointestinal cancer, cilt.44, ss.354-6, 2013 (SCI-Expanded)

XLVIII. **Efficiency and Side Effects of Sorafenib Therapy for Advanced Hepatocellular Carcinoma: A Retrospective Study by the Anatolian Society of Medical Oncology**
Berk V., Kaplan M. A., Tonyali O., Buyukberber S., Balakan O., ÖZKAN M., Demirci U., Ozturk T., Bilici A., Tastekin D., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, cilt.14, sa.12, ss.7367-7369, 2013 (SCI-Expanded)

XLIX. **The biochemical effectiveness of N-acetylcysteine in experimental spinal cord injury in rats.**
Hanci V., Kerimoğlu A., Koca K., Başkesen A., Kiliç K., Taştekin D.
Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES, cilt.16, ss.15-21, 2010 (SCI-Expanded)

L. **Correlation between the erythrocyte sedimentation rate and blood nitric oxide levels in rabbits?**
Uzun M., Saral S., Atakisi O., Yapar K., Uzlu E., Citil M., Tastekin D., Erdogan H. M.
Scandinavian Journal of Laboratory Animal Science, cilt.35, sa.1, ss.53-56, 2008 (SCI-Expanded)

LI. **Investigation of free radical scavenging enzyme activities and lipid peroxidation in liver tissue of zinc deficient rats**
Kaya H., Taysi S., Kaya A., Boyuk A., DURSUN H., Islamoglu Y., Tastekin D., Cikman O.
Asian Journal of Chemistry, cilt.20, sa.2, ss.1068-1074, 2008 (SCI-Expanded)

LII. **Hypoglycaemic effect of Artemisia herba-alba in experimental hyperglycaemic rats**
Taştekin D., ATASEVER M., Adigüzel G., Keleş M., Taştekin A.
Bulletin of the Veterinary Institute in Pulawy, cilt.50, sa.2, ss.235-238, 2006 (SCI-Expanded)

Diğer Dergilerde Yayınlanan Makaleler

I. **Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study**
Paksoy N., Ferhatoglu F., DOĞAN İ., Khanmammadov N., Bozbey H. U., KARABULUT S., Tastekin D.
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, cilt.37, sa.4, ss.478-483, 2022 (ESCI)

II. **Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers**
Karabulut S., Topalgokceli M. S., Tastekin D.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, cilt.6, sa.1, ss.12-15, 2022 (ESCI)

III. **WHAT'S NEW IN METASTATIC COLON CANCER TREATMENT?**
Karabulut S., Karabulut M., Tastekin D.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI, cilt.84, sa.3, ss.425-429, 2021 (ESCI)

IV. **The Association of Pancreatic Cancer and PALB2 Gene Mutations in the Turkish Population**
Turkcan G. K., Odemis D., Avsar M., Tuncer S. B., Erciyas S., Erdogan Ö., Tastekin D., Karabulut S., Kaytan E., Yazici H.
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, cilt.34, sa.4, ss.283-290, 2019 (ESCI)

V. **Importance of Performing Radiotherapy and Chemotherapy in the Same Clinic and Bad Prognostic**

Factors for Small-cell Lung Cancer Patients
Kiziltan H. S., TAŞTEKİN D., ERİŞ A. H., Taspinar O., Ismaylova M., MAYADAĞLI A.
BEZMIALEM SCIENCE, cilt.4, sa.2, ss.51-55, 2016 (ESCI)

VI. **Clinical Significance of Serum Galectin-3 Levels in Gastric Cancer Patients.**
Tas F., Bilgin E., Tastekın D., Erturk K., Duranyıldız D.
Journal of gastrointestinal cancer, cilt.47, ss.182-6, 2016 (Scopus)

VII. **Serum IGF-1 and IGFBP-3 levels as clinical markers for patients with lung cancer**
Tas F., Bilgin E., Tastekin D., Erturk K., Duranyildiz D.
BIOMEDICAL REPORTS, cilt.4, sa.5, ss.609-614, 2016 (ESCI)

VIII. **Clinical significance of serum laminin levels in patients with lung cancer**
Tas F., Bilgin E., Tastekin D., Erturk K., Duranyildiz D.
BIOMEDICAL REPORTS, cilt.4, sa.4, ss.485-488, 2016 (ESCI)

IX. **Levels of serum fibronectin as a biomarker in gastric cancer patients: Correlation with clinical diagnosis and outcome**
Tas F., Bılgın E., Karabulut S., Tastekın D., Duranyıldız D.
MOLECULAR AND CLINICAL ONCOLOGY, cilt.4, sa.4, ss.655-659, 2016 (ESCI)

X. **Clinical significance of serum protease-activated receptor-1 levels in gastric cancer patients**
Tas F., Karabulut S., Tastekin D., Duranyildiz D.
BIOMEDICAL REPORTS, cilt.4, sa.4, ss.489-492, 2016 (ESCI)

XI. **The Effects of Topical Insulin Application on Wound Healing**
Kargin S., Tastekin D., Kilic K., Cezik A., Cakir M., Kucukkartallar T., Kokbudak N.
EUROPEAN JOURNAL OF GENERAL MEDICINE, cilt.12, sa.4, ss.302-306, 2015 (ESCI)

XII. **Treatment modalities in primary gastric lymphoma: the effect of rituximab and surgical treatment. A study by the Anatolian Society of Medical Oncology**
Mehmet K., Sener C., Uyeturk U., Seker M., Tastekin D., Tonyali O., Balakan O., Yazici O. K., Urakci Z., Isikdogan A., et al.
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, cilt.18, sa.4, ss.273-278, 2014 (ESCI)

XIII. **[The opinions of Turkish physicians about the tasks of tuberculosis central dispensary].**
Tanrikulu A., Palanci Y., Eren D., Yilmaz G., Karaca M., Abakay A., Taştekin D.
Tuberkuloz ve toraks, cilt.57, ss.32-7, 2009 (ESCI)

Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

I. **The frequencies and prognostic significance of ABO blood and rhesus (D) groups in HER2-positive gastric cancer**
Dogan I., Gurbuz M., Aydin E., Tastekin D., Karabulut S., Utkan G.
ESMO 22nd World Congress on Gastrointestinal Cancer, ELECTR NETWORK, 1 - 04 Temmuz 2020, cilt.31

II. **Trastuzumab-based treatment of HER2-positive metastatic gastric cancer**
Dogan I., Karabulut S., Tastekin D., Paksoy N., Sakar B., Vatansever S.
ESMO 22nd World Congress on Gastrointestinal Cancer, ELECTR NETWORK, 1 - 04 Temmuz 2020, cilt.31

III. **Does nutritional status affect treatment tolarability, response, and survival in metastatic colorectal cancer patients? Results of prospective multicenter study**
Karabulut S., Dogan I., Afsar C. U., Karabulut M., Karaman S., Ferhatoglu F., Tastekin D.
Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology, San-Francisco, Kostarika, 23 - 25 Ocak 2020, cilt.38

IV. **Mide Kanserinde Serum Interleukin-29, Interleukin-32 ve Tumor Necrosis Factor Alpha'nın Klinik Önemi**
ERTÜRK K., TAŞTEKİN D., SERİLMEZ M., BİLGİN DOĞRU E., H. U., VATANSEVER S.
3. Ulusal İmmüno-Onkoloji ve Hedefe Yönelik Kanser Tedavileri Kongresi, Antalya, Türkiye, 11 - 15 Mayıs 2016, ss.1

V. **Rektum kanserinde neoadj. sib-vmat yanıtının difüzyon MR ve serum apoptoz marker düzeyleri ile**

değerlendirilmesi

GÜRDAL N., FAYDA E. M., BAKIR B., Alishev N., GEZER U., TAŞTEKİN D., Çiftçi R., AKBAŞ U., ŞAHİN D., BALIK E., et al.
12. Ulusal Radyasyon Onkolojisi Kongresi, Antalya, Türkiye, 20 - 24 Nisan 2016, ss.45

VI. **Nüks meme kanserinde reoperatif sentinel lenf nodu biyopsisi: Aksilla korunabilir mi?**

Karanlık H., Özgür İ., Kılıç B., Şanlı Y., Önder S., Taştekin D., Şen F.
13. Ulusal Meme Hastalıkları Kongresi, 2015, Antalya, Türkiye, 21 - 25 Ekim 2015, ss.1

VII. **The role of adhesion molecules in hepatocellulary carcinoma**

Tastekin D., DIKILITAS M., HARPUTLUOGLU H., Erturk K., CELEBI K., Sen F., BOZBEY H. U.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33

VIII. **The prognostic value of lymph node ratio in patients with curatively resected pancreatic adenocarcinoma.**

Turan N., Araz M., Algin E., Unal O. U., Benekli M., Tastekin D., Dane F., Unek T., Eren T., Turkmen E., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33

IX. **Clinical significance of serum macrophage migration inhibitory factor (MIF) level in breast cancer.**

CIFTCI R., Tas F., AKSIT E., Vatansever S., KARABULUT S., Sen F., YILDIZ I., Keskin S., BOZBEY H. U., Kilic L., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32

X. **Clinical significance of serum epithelial cell adhesion molecule (EPCAM) cud vascular cell adhesion molecule-1 (VCAM-1) levels in lung cancer.**

KARABULUT S., Tastekin D., CIFTCI R., Tambas M., DAGOGLU N., Guveil M. E., Tas F., Duranyildiz D., Aydiner A.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32

XI. **Clinical significance of serum caveolin-1 levels in melanoma.**

Tastekin D., KARABULUT S., DURANYILDIZ D., Tas F.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32

XII. **Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma**

Ciftci R., Karabulut S., Tastekin D., Sen F., Kilic L., Yildiz I., Keskin S., Tas F.
European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Hollanda, 27 Eylül - 01 Ekim 2013, cilt.49

XIII. **The effects of variability of mean erythrocyte corpuscular volume (MCV) in patients with advanced stage gastrointestinal stromal tumor (GIST) using imatinib on progression free survival**

Cetin B., TAŞTEKİN D., Aktas B., Guler T., Kaplan M. A., Berk V., Gumusay O., Dane F., Ozkan M., Benekli M.
European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Hollanda, 27 Eylül - 01 Ekim 2013, cilt.49

XIV. **Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer.**

Turan N., Dane F., Unal O. U., Benekli M., Kara H. V., Koca D., Balvan O., Eren T., Tastekin D., Dogan E., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31

XV. **Coagulation assays in breast cancer: Correlation of plasma D-dimer with tumor load and invasiveness in breast cancer patients.**

Karabulut S., Kilic L., Ciftci R., Yildiz I., Sen F., Keskin S., Tastekin D., Tas F.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31

XVI. **Comparison of mucosal and cutaneous melanoma in the head and neck region: Different clinical features and similar outcomes.**

Ciftci R., Keskin S., Karabulut S., Yildiz I., Kilic L., Sen F., Tastekin D., Tas F.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31

Desteklenen Projeler

Taştekin D., Diğer Özel Kurumlarca Desteklenen Proje, RECITE: Gastrointestinal veya Kolorektal Kanserin Tedavisi için FOLFOX bazlı Kemoterapi Alan Hastalarda Kemoterapiye Bağlı Trombositopeninin Tedavisinde Romiplostimi Değerlendiren Faz 3, Randomize Plasebo Kontrollü Çift Kör Çalışma, 2020 - 2021
BADEMLER S., HOSNI SOBHI ALSAADONI H., PENÇE S., ŞABANÇELEBİ S., Yükseköğretim Kurumları Destekli Proje, Mide Kanserli Hastalarda miRNA Seviyelerinin Belirlenmesi, 2016 - 2018
ERGEN H. A., HOSNI SOBHI ALSAADONI H., TAŞTEKİN D., YEŞİLKAYA F., Yükseköğretim Kurumları Destekli Proje, Kolon Kanseri Hastalarında MACC1 FİLAMİN A VE FBXW7 Genlerinin Ekspresyon Seviyelerinin İncelenmesi, 2016 - 2018
TAŞTEKİN D., Yükseköğretim Kurumları Destekli Proje, Böbrek Kanseri Hastalarından Alınan Doku Örneklerinde miRNA Ekspresyonlarının İncelenmesi, 2015 - 2017

Metrikler

Yayın: 81
Atıf (WoS): 322
Atıf (Scopus): 391
H-İndeks (WoS): 10
H-İndeks (Scopus): 11